Science-Driven.
Patient-Focused.
For nearly four decades, Ferro Pharma has been at the forefront of pharmaceutical innovation — transforming scientific breakthroughs into medicines that matter.
Mission, Vision & Purpose
Our Mission
To discover, develop, and deliver innovative medicines that address unmet medical needs and improve the quality of life for patients worldwide.
Our Vision
A world where every patient has access to the most effective, safe, and affordable treatments — regardless of geography or circumstance.
Our Purpose
We exist to serve patients. Every decision we make — from early research to commercial launch — is guided by the impact on the people who depend on our medicines.
Our Core Values
Integrity
We hold ourselves to the highest ethical standards in everything we do — from clinical trials to commercial practices.
Innovation
We embrace bold science and creative thinking, investing in platforms and technologies that others consider too risky.
Patient-Centricity
Patients are at the center of every decision. Their needs, voices, and outcomes guide our priorities.
Global Responsibility
We are committed to equitable access, environmental stewardship, and positive impact in every community we serve.
Scientific Rigor
We pursue truth relentlessly, applying the highest standards of evidence to every compound we advance.
Excellence
We set ambitious goals and hold ourselves accountable for delivering results that matter to patients and shareholders alike.
Leadership Team
Experienced leaders united by a shared commitment to scientific excellence and patient impact.
Dr. Elena Marchetti
Chief Executive Officer
Former Head of Global Oncology at Novartis. 25+ years driving breakthrough therapies from bench to bedside across 60+ markets.
Dr. James Okafor
Chief Scientific Officer
PhD in Molecular Biology from MIT. Led discovery of 3 approved drugs. Pioneer in targeted protein degradation and bispecific antibody platforms.
Sarah Chen
Chief Financial Officer
Former Goldman Sachs Managing Director. Orchestrated $4.2B in strategic acquisitions and two successful IPOs in the life sciences sector.
Dr. Raj Patel
Chief Medical Officer
Board-certified cardiologist and clinical researcher. Oversaw 40+ Phase II/III trials across cardiovascular and metabolic disease areas.
Maria Santos
Chief Operating Officer
20 years in pharmaceutical operations. Scaled manufacturing from 3 to 18 global facilities while achieving ISO 9001 and GMP compliance.
Dr. Thomas Weber
SVP, Regulatory Affairs
Former FDA reviewer with deep expertise in biologics and small molecules. Achieved 12 regulatory approvals across US, EU, and APAC.
38 Years of Innovation
Founded
Ferro Pharma GmbH established in Basel, Switzerland with a focus on cardiovascular research.
First Approval
Received FDA approval for our first cardiovascular compound, establishing our clinical credibility.
Global Expansion
Opened research centers in Boston, Tokyo, and Singapore. Expanded to 30+ countries.
Oncology Division
Launched dedicated oncology R&D division following acquisition of BioTarget Inc.
Biologics Platform
Invested $1.2B in next-generation biologics manufacturing and bispecific antibody technology.
Cardivex Approved
First-in-class cardiac myosin activator approved in 47 countries, transforming HFrEF treatment.
mRNA Pipeline
Launched personalized cancer vaccine program leveraging proprietary mRNA delivery technology.